Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;36(1):45-54.
doi: 10.1007/s11096-013-9833-5. Epub 2013 Aug 11.

Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer

Affiliations
Review

Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer

Lorena Rocha Ayres et al. Int J Clin Pharm. 2014 Feb.

Abstract

Background: Oral treatment in women with breast cancer has been increasingly used. However, a potentially negative side of oral medication is poor patient adherence and/or discontinuation, which reduces the treatment effectiveness, accelerating progression of the disease and reducing the patient survival rate.

Aim of the review: To compare the rates of adherence and/or discontinuation and the methodologies used to assess these outcomes. It was conducted an integrative review of original articles published from 2000 to 2012, in which their primary outcome was to quantify medication adherence and/or discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer.

Methods: Original studies were searched in the PubMed/MEDLINE, Scopus, Embase and SciELO databases. The Medical Subject Heading was used to define descriptors. The descriptor "breast neoplasms" was used in all combinations. Each of the descriptors "medication adherence" and "patient compliance" were combined with each of the following descriptors "tamoxifen", "aromatase inhibitors", "selective estrogen receptor modulators", or the terms "letrozole", "anastrozole", and "exemestane".

Results: Twenty-four original articles were included. Our study showed a wide range of adherence and discontinuation rates, ranging from 45-95.7 and 12-73 %, respectively. Regarding the methodological development of the selected articles, a high prevalence (87.5 %) of prospective and/or retrospective longitudinal studies was found. In addition, there was a high prevalence of studies using a database (70.8 %). Among some of the studies, it was shown that patient adherence to hormonal therapy gradually reduces, while discontinuation increases during the treatment.

Conclusions: It was observed a great diversity among rates of adherence and/or discontinuation of hormonal therapy for breast cancer, which may be due to a lack of methodology standardization. Therefore, adequate and validated methods to ensure reliability of the results and allow comparison in the literature are needed. Furthermore, adherence decreases and discontinuation increases over time, suggesting the need for patient continuous education and a pharmacotherapeutic follow up by health professionals to improve these clinical outcomes.

PubMed Disclaimer

References

    1. Br J Cancer. 2012 Oct 9;107(8):1249-56 - PubMed
    1. Breast Cancer Res Treat. 2012 May;133(1):367-73 - PubMed
    1. J Manag Care Pharm. 2011 Apr;17(3):213-23 - PubMed
    1. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
    1. Ann Oncol. 2012 Apr;23(4):882-90 - PubMed

MeSH terms

Substances

LinkOut - more resources